Advertisement

Pharmacokinetic studies with sustained-release formulations of levodopa in healthy volunteers

  • M. Gerlach
  • B. Gebhardt
  • W. Kuhn
  • H. Przuntek
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Summary

On the basis of the results of a large number of studies of the correlation between plasma levodopa levels and the occurrence of mobility disorders, it was concluded that side-effects such as dyskinesia, end-of-dose, peak-dose and on-off phenomena, which occur especially during levodopa long- term treatment of Parkinson patients, may be caused by fluctuations in the plasma levodopa levels. Some preliminary trials using sustained-release formulations were not up to expectations. Still, we studied the question of whether it might not be possible after all to obtain sustained plasma levodopa levels over prolonged periods of time with levodopa sustained-release (S. R.) formulations, without causing a high initial peak. For this purpose, we compared the pharmacokinetics of six different levodopa S. R. formulations with a standard preparation in two randomized cross-over trials in healthy male volunteers.

Although the levodopa S. R. formulations prolonged the time to peak blood levels in all cases, a plateau that was constant over a longer period of time could not be obtained. However, none of the S. R. preparations studied gave rise to a high initial peak of the plasma levodopa concentration. The levodopa concentrations had again returned to endogenous levels within no more than 8 hours of administration of all six levodopa S. R. formulations.

Keywords

Levodopa Dose Levodopa Concentration Plasma Levodopa Plasma Levodopa Concentration Levodopa Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eriksson T, Magnusson T, Carlsson A, Granerus AK (1984) “On-off” phenomenon in Parkinson’s disease: correlation to the concentration of Dopa in plasma. J Neural Transm 59: 229–240PubMedCrossRefGoogle Scholar
  2. Fahn S (1974) “On-off” phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441PubMedCrossRefGoogle Scholar
  3. Gerlach M, Klaunzer N, Przuntek H (1986) Determination of L-Dopa and 3-O-methyl- Dopa in human plasma by extraction using C18 cartridges followed by high-performance liquid chromatographic analysis with electrochemical detection. J Chromatogr 380: 379–385CrossRefGoogle Scholar
  4. Gerlach M, Gebhardt B, Kuhn W, Przuntek H (1986) Die Abhängigkeit der Resorption des L-Dopa von Galenik und veränderter Magensaftsekretion des Parkinson-Patienten. In: Fischer PA (ed) Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel, pp 271–279Google Scholar
  5. Gundert-Remy UR, Hildebrandt R, Stiehl A, Weber E, Zürcher G, Da Prada M (1983) Intestinal absorption of levodopa in man. Eur J Clin Pharmacol 25: 69–72PubMedCrossRefGoogle Scholar
  6. Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson’s disease. Brain 107: 487–506PubMedCrossRefGoogle Scholar
  7. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429–436PubMedCrossRefPubMedCentralGoogle Scholar
  8. Hornykiewicz O (1977) Biogenic amines in the central nervous system. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology vol 29, part 3. North-Holland, Amsterdam, pp 495–483Google Scholar
  9. Jenner P, Boyce S, Marsden CD (1986) Effect of repeated L-Dopa administration on striatal dopamine receptor function in the rat. In: Fahn S et al (eds) Recent developments in Parkinson’s disease. Raven Press, New York, pp 189–203Google Scholar
  10. Juncos JL, Fabborini G, Mouradian MM, Serrati C, Kask AM, Chase TN (1987) Controlled release levodopa treatment of motor fluctuations in Parkinson’s disease. Neurol Neurosurg Psychiatry 50: 194–198CrossRefGoogle Scholar
  11. Leenders K, Palmer A, Turton D, Quinn N, Firnau G, Garnett S, Nahmias C, Jones T, Marsden CD (1986) Dopa uptake and dopamine receptor binding visualized in the human brain in vivo. In: Fahn S etal (eds) Recent development in Parkinson’s disease. Raven Press, New York, pp 103–113Google Scholar
  12. Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD (1986) Single-dose study of slow release preparation of levodopa and benseracide (Madopar HBS) in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 493–496Google Scholar
  13. Meier J, Rettig H, Hess H (1981) Biopharmazie-Theorie und Praxis der Pharmakokinetik. G Thieme, Stuttgart New York Mena MA, Muradas V, Bazan E, Reiviz J, de Yebenes JG (1986) Pharamcokinetics of L- Dopa in patients with Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 481–486Google Scholar
  14. Nutt JG, Fellman JH (1984) Pharmacokinetics of Levodopa. Clin Neuropharmacol 7: 35–49PubMedCrossRefGoogle Scholar
  15. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The “On-off” phenomenon in Parkinson’s disease. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  16. Nutt JG, Woodward WR, Carter JH (1986) Clinical and biochemical studies with controlled-release levodopa/carbidopa. Neurology 36: 1206–1211PubMedCrossRefGoogle Scholar
  17. Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedCrossRefGoogle Scholar
  18. Sweet RD, Fletcher H, Dowell MC (1974) Plasma dopa concentrations and the “on-off” effect after chronic treatment of Parkinson’s disease. Neurology 24: 953–956PubMedCrossRefGoogle Scholar
  19. Tolosa ES, Martin WE, Cohen HP, Jacobsen RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • M. Gerlach
    • 1
  • B. Gebhardt
    • 1
  • W. Kuhn
    • 1
  • H. Przuntek
    • 2
  1. 1.Department of NeurologyUniversity of WürzburgWürzburgGermany
  2. 2.Department of Neurology, St. Joseph-HospitalUniversity of BochumBochumFederal Republic of Germany

Personalised recommendations